Filing Details
Prelude Therapeutics Inc (NASDAQ:PRLD) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:PRLD
Prelude Therapeutics Inc (PRLD) Files Quarterly Report for Q0
Prelude Therapeutics Inc (NASDAQ:PRLD) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
At publication ·
What changed
Prelude Therapeutics Inc (NASDAQ:PRLD) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Prelude Therapeutics Inc (NASDAQ: PRLD) filed its quarterly report (Form 10-Q) with the SEC on August 11, 2026.
- The company's stock trades at $5.32 with a market capitalization of $89.1 million.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance, including updated risk factors and changes in business conditions since the last annual filing.
Market Context
Prelude Therapeutics Inc's stock currently trades at $5.32 with a market capitalization of $89.1M.
The 10-Q provides Prelude Therapeutics Inc's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Prelude Therapeutics Inc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PRLD Stock Page
Frequently Asked Questions
Where can I read PRLD's SEC filings?
Browse all filings on our PRLD SEC filings page.
What types of SEC filings does Prelude Therapeutics Inc file?
Public companies like Prelude Therapeutics Inc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.